Tilray | TRLY - Debt

Stock Price
10.70
Daily Change
-0.15 -1.38%
Monthly
-11.13%
Yearly
838.60%
Q1 Forecast
10.37

Tilray reported $640.95M in Debt for its fiscal quarter ending in June of 2022.





Debt Change Date
Acasti Pharma USD 0 0 Sep/2024
Akebia Therapeutics USD 46.51M 7.82M Mar/2025
Alaunos Therapeutics USD 10.99M 5.78M Mar/2023
Aurora Cannabis CAD 100.34M 1.29M Sep/2025
Avita Medical AUD 44.59M 1.4M Jun/2025
Canopy Growth CAD 259.33M 68.47M Sep/2025
Cronos Group USD 2.01M 159K Jun/2025
Dianthus Therapeutics USD 1.28M 45K Sep/2025
Divis Laboratories Ltd INR 40M 40M Mar/2025
Ionis Pharmaceuticals USD 2.33B 1.1B Dec/2025
IQVIA Holdings USD 15.72B 767M Dec/2025
Knight Therapeutics CAD 106.24M 1.5M Sep/2025
Moderna USD 734M 7M Sep/2025
Organon & Co USD 8.83B 68M Sep/2025
Revvity USD 3.37B 5.86M Sep/2025
Tectonic Therapeutic USD 876K 115K Dec/2024
Tilray USD 640.95M 35.17M Jun/2022
Viatris USD 14.44B 318.8M Sep/2025
Xeris Pharmaceuticals USD 257.65M 431K Sep/2025